Hansa Biopharma AB (publ) (HNSA) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Hansa Biopharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.051 -- 00:00:05.172 Good day and welcome to the Hansa Biopharma second quarter and first 00:00:05.172 -- 00:00:09.513 half year 2026 financial results conference call. 00:00:09.513 -- 00:00:12.133 All participants will be in listen only mode. 00:00:12.133 -- 00:00:17.054 Should you need assistance, please signal a conference specialist by pressing the star 00:00:17.054 -- 00:00:22.255 key followed by zero. After today's presentation, there will be an opportunity to ask 00:00:22.255 -- 00:00:27.276 questions. To ask a question, you may press star then one on a 00:00:27.276 -- 00:00:32.297 touch tone phone. To withdraw your question, please press star then two. 00:00:32.297 -- 00:00:36.898 Please note this event is being recorded. I would now like to turn the conference over 00:00:36.898 -- 00:00:41.479 to Hansa Biopharma CEO, Renée Aguirre-Lucander. 00:00:41.479 -- 00:00:44.019 Please go ahead. 00:00:44.380 -- 00:00:46.540 Thank you very much. 00:00:46.540 -- 00:00:49.061 Good afternoon and good morning, everybody. 00:00:49.061 -- 00:00:54.642 Welcome to the Hansa Biopharma Conference call to review the Q2 results for 2026. 00:00:54.642 -- 00:00:58.580 I'm Renée Aguirre-Lucander, CEO for Hansa Biopharma. 00:00:58.580 -- 00:01:03.384 Joining me today is Adam Cutler, Chief Financial Officer, Richard Philipson, Chief Medical 00:01:03.384 -- 00:01:09.148 Officer, and Maria Tarnson, Chief Operating Officer and President of the US. 00:01:09.148 -- 00:01:12.411 Please turn to the next page. 00:01:12.411 -- 00:01:15.393 Please allow me to draw your attention to the fact that we'll be making forward-looking 00:01:15.393 -- 00:01:20.157 statements during the presentation, and you should therefore apply appropriate caution. 00:01:20.157 -- 00:01:22.398 Next slide...